Timothy B. Lowinger
2018
In 2018, Timothy B. Lowinger earned a total compensation of $1.1M as Senior Vice President and Chief Scientific Officer at Mersana Therapeutics, a 103% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $128,000 |
|---|---|
| Option Awards | $534,681 |
| Salary | $382,000 |
| Other | $6,000 |
| Total | $1,050,681 |
Lowinger received $534.7K in option awards, accounting for 51% of the total pay in 2018.
Lowinger also received $128K in non-equity incentive plan, $382K in salary and $6K in other compensation.
Rankings
In 2018, Timothy B. Lowinger's compensation ranked 8,986th out of 14,244 executives tracked by ExecPay. In other words, Lowinger earned more than 36.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,986 out of 14,244 | 37th |
Division Manufacturing | 3,577 out of 5,762 | 38th |
Major group Chemicals And Allied Products | 1,350 out of 2,125 | 37th |
Industry group Drugs | 1,133 out of 1,814 | 38th |
Industry Pharmaceutical Preparations | 882 out of 1,388 | 37th |
Source: SEC filing on April 23, 2019.
Lowinger's colleagues
We found three more compensation records of executives who worked with Timothy B. Lowinger at Mersana Therapeutics in 2018.
News
Mersana Therapeutics CEO Anna Protopapas' 2023 pay jumps 56% to $4.5M
April 26, 2024
Mersana Therapeutics CEO Anna Protopapas' 2022 pay falls 66% to $2.8M
April 28, 2023
Mersana Therapeutics CEO Anna Protopapas' 2021 pay jumps 226% to $8.3M
April 29, 2022
Mersana Therapeutics Chief Medical Officer Arvin Yang receives $4.5M in 2020
April 27, 2021
Mersana Therapeutics CEO Anna Protopapas' 2019 pay falls 33% to $1.7M
April 20, 2020
Mersana Therapeutics CEO Anna Protopapas' 2018 pay jumps 184% to $2.6M
April 23, 2019